search

Active clinical trials for "Hypertension"

Results 2891-2900 of 5863

A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular...

GlaucomaOpen-Angle1 more

The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.

Completed5 enrollment criteria

A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients...

Hypertension

The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other biomarkers.

Completed10 enrollment criteria

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing...

Essential Hypertension

This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension

Completed12 enrollment criteria

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension...

Open-angle GlaucomaOcular Hypertension

The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

Completed12 enrollment criteria

A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular...

Open-Angle GlaucomaOcular Hypertension

The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension. This global study will be conducted in the US (C-07-64, NCT00672997) and Japan (C-08-08, NCT00760539).

Completed15 enrollment criteria

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary...

Ocular HypertensionGlaucoma

The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.

Completed12 enrollment criteria

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to...

Essential Hypertension

The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential hypertension.

Completed24 enrollment criteria

Effects of Continuous Positive Airway Pressure (CPAP) in Patients With Resistant Hypertension and...

Obstructive Sleep ApneaRefractory Hypertension

Obstructive sleep apnea (OSA) is an important cause of refractory hypertension but the impact of treatment with continuous positive airway pressure (CPAP) is not completely understood. The aim of this project is to study the effects of CPAP on blood pressure control and its influences on cardiac remodeling and arterial stiffness in patients with refractory hypertension and moderate or severe OSA.

Completed4 enrollment criteria

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension....

ObesityHypertension

The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.

Completed32 enrollment criteria

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

Type 2 DiabetesHypertension

Insulin resistance has been implicated as the central pathogenetic feature of cardiovascular risk factor cluster that includes hypertension, impaired glucose tolerance, diabetes, dyslipidemia, and hemostatic disorders. Recent evidence suggests that increased levels of free fatty acids (FFA) in obese subjects is a leading candidate in the pathogenesis of insulin resistance (1-4). In our preliminary studies on the effect of FFA on insulin secretion and action (lipotoxicity), we have observed that the infusion of Intralipid/heparin to increase FFA ~ four-fold-baseline levels for 48 hours results in a significant and reproducible raise in systolic and diastolic blood pressure (BP) in obese African American subjects with and without diabetes. The increase in blood pressure is apparent after 12 hours of infusion, reaching a peak increment of 32 mm Hg in systolic and 14 mm Hg in diastolic pressure at 24 hours. These preliminary findings indicate that, in addition to the well-known effect on insulin resistance, sustained elevation of FFA results in the development of an acute metabolic syndrome.

Completed15 enrollment criteria
1...289290291...587

Need Help? Contact our team!


We'll reach out to this number within 24 hrs